Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Merck
AstraZeneca
Medtronic
McKesson

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,649,305

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,649,305
Title:PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic
Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one- , is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells. ##STR00001##
Inventor(s): Tapolsky; Gilles H. (Louisville, KY), Chand; Pooran (Birmingham, AL)
Assignee: Advanced Cancer Therapeutics, LLC (Louisville, KY)
Application Number:14/388,983
Patent Claims:1. A compound for the treatment of cancer, consisting of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one- , or a pharmaceutically acceptable salt thereof, having the formula: ##STR00027##

2. The compound of claim 1, wherein the cancer is selected from the group consisting of glioblastoma multiforme, skin cancers, connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic cancers, ovarian and reproductive organ cancers, cervical cancers, uterine cancers, anogenital cancers, kidney cancers, bladder cancers, liver cancers, colorectal or colon cancers and digestive (GI) tract cancers, prostate cancers and reproductive organ cancers, central nervous system (CNS) cancers, retinal cancer, blood, and lymphoid cancers, and head and neck cancers.

3. A pharmaceutical composition for the treatment of cancer, comprising: (a) an effective amount of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one or a pharmaceutically acceptable salt thereof; and (b) at least one pharmaceutically acceptable carrier.

4. The pharmaceutical composition of claim 3, further comprising a second anti-cancer agent.

5. The pharmaceutical composition of claim 4, wherein the second anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, cis-platin, carboplatin, oxaliplatin, doxorubicin, vincristine, vinblastine, 5-FU, irinotican, methotraxate, leucovorin, bevacizumab, cetuximab, sutinibib, imatinib, temozolomide, and gemcitabine.

6. The pharmaceutical composition of claim 3, wherein the cancer is selected from the group consisting of glioblastoma multiforme, skin cancers, connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic cancers, ovarian and reproductive organ cancers, cervical cancers, uterine cancers, anogenital cancers, kidney cancers, bladder cancers, liver cancers, colorectal or colon cancers and digestive (GI) tract cancers, prostate cancers and reproductive organ cancers, central nervous system (CNS) cancers, retinal cancer, blood, and lymphoid cancers, and head and neck cancers.

7. A method of treating cancer, the method comprising administering to a subject in need thereof an effective amount of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one or a pharmaceutically acceptable salt thereof.

8. The method of claim 7, wherein the cancer is selected from the group consisting of glioblastoma multiforme, skin cancers, connective tissue cancers, adipose cancers, breast cancers, lung cancers, stomach cancers, pancreatic cancers, ovarian and reproductive organ cancers, cervical cancers, uterine cancers, anogenital cancers, kidney cancers, bladder cancers, liver cancers, colorectal or colon cancers and digestive (GI) tract cancers, prostate cancers and reproductive organ cancers, central nervous system (CNS) cancers, retinal cancer, blood, and lymphoid cancers, and head and neck cancers.

9. The method of claim 8, further comprising administering a second anti-cancer agent.

10. The method of claim 9, wherein the second anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, cis-platin, carboplatin, oxaliplatin, doxorubicin, vincristine, vinblastine, 5-FU, irinotican, methotraxate, leucovorin, bevacizumab, cetuximab, sutinibib, imatinib, temozolomide, and gemcitabine.

11. The method of claim 10, wherein the second anti-cancer agent is co-administered with (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one- .

12. A method of treating a tumor, the method comprising administering to a subject in need thereof an effective amount of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, further comprising administering a second anti-cancer agent.

14. The method of claim 13, wherein the second anti-cancer agent is selected from the group consisting of paclitaxel, docetaxel, cis-platin, carboplatin, oxaliplatin, doxorubicin, vincristine, vinblastine, 5-FU, irinotican, methotraxate, leucovorin, bevacizumab, cetuximab, sutinibib, imatinib, temozolomide, and gemcitabine.

15. The method of claim 14, wherein the second anti-cancer agent is co-administered with (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one- .

16. A method of inhibiting glycolytic flux in a cell, the method comprising contacting the cell with an effective amount of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one or a pharmaceutically acceptable salt thereof.

17. A method of inhibiting enzymatic activity of PFKFB3 in a cell, the method comprising contacting the cell with an effective amount of (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one or a pharmaceutically acceptable salt thereof.

Summary for Patent:   Request a Trial

PCT Information
PCT FiledMarch 14, 2013PCT Application Number:PCT/US2013/031159
PCT Publication Date:October 03, 2013PCT Publication Number:WO2013/148228

Details for Patent 9,649,305

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Request a Trial Advanced Cancer Therapeutics, LLC (Louisville, KY) 2037-10-23 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Request a Trial Advanced Cancer Therapeutics, LLC (Louisville, KY) 2037-10-23 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Request a Trial Advanced Cancer Therapeutics, LLC (Louisville, KY) 2037-10-23 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
AstraZeneca
Moodys
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.